[an error occurred while processing this directive] | [an error occurred while processing this directive]
Clinical efficacy of concurrent chemoradiotherapy for cervical adenocarcinoma and salvage treatment of residual lesions
Ma Jiabin, Hu Ke, Zhang Fuquan
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
AbstractObjective To evaluate the clinical efficacy of concurrent chemoradiotherapy for cervical adenocarcinoma, and to analyze the treatment and evaluate the prognosis of patients with residual lesions after definitive radiotherapy. Methods Clinical data of 109 patients with locally advanced cervical adenocarcinoma treated from January 2005 to February 2016 were analyzed retrospectively. The prescription dose of external irradiation was 50.4Gy,28 fractions, and the point A dose of brachytherapy was 30-36Gy,5-7 fractions. Cisplatin or paclitaxel was used as concurrent chemotherapy regimen. Clinical efficacy was evaluated after concurrent chemoradiotherapy. Patients with clinical partial remission (PR) after treatment might receive salvage surgery and/or chemotherapy and/or radiotherapy. The survival analysis was performed with Kaplan Meier method. Results The median follow-up period was 48 months, and the 3-year and 5-year overall survival rates were 74.1% and 58.5%, respectively. After concurrent chemoradiotherapy, 72 patients (66.1%) achieved clinical complete remission, and 31 patients (28.4%) obtained PR. After receiving salvage treatment, the 3-year overall survival rate and progression-free survival rate of PR patients were 53.1% and 40.5%, respectively. Only 4 patients (3.7%) and 2 patients (1.8%) had grade 3 or greater urinary and gastrointestinal toxicity after definitive treatment. Conclusion For patients with cervical adenocarcinoma who have clinical residual lesions after primary treatment, salvage treatment should be actively taken in order to improve survival outcomes.
Ma Jiabin,Hu Ke,Zhang Fuquan. Clinical efficacy of concurrent chemoradiotherapy for cervical adenocarcinoma and salvage treatment of residual lesions[J]. Chinese Journal of Radiation Oncology, 2020, 29(9): 762-766.
Ma Jiabin,Hu Ke,Zhang Fuquan. Clinical efficacy of concurrent chemoradiotherapy for cervical adenocarcinoma and salvage treatment of residual lesions[J]. Chinese Journal of Radiation Oncology, 2020, 29(9): 762-766.
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI:10.3322/caac.21492. [2] Alfsen GC, Thoresen SO, Kristensen GB, et al. Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups:a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990[J]. Cancer, 2000, 89(6):1291-1299. [3] Smith, HO, Tiffany MF, Qualls CR, et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study[J]. Gynecol Oncol, 2000, 78(2):97-105. DOI:10.1006/gyno.2000.5826. [4] Wang SS, Sherman ME, Hildesheim A, et al. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000[J]. Cancer, 2004, 100(5):1035-1044. DOI:10.1002/cncr.20064. [5] Zhou J, Wu SG, Sun JY, et al. Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy:a population-based analysis[J]. J Cancer Res Clin Oncol, 2017, 143(1):115-122. DOI:10.1007/s00432-016-2246-9. [6] Hu K, Wang W, Liu X, et al. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy[J]. Radiation Oncology, 2018, 13(1):249-255. DOI:10.1186/s13014-018-1197-5. [7] Chen JL, Huang CY, Huang YS, et al. Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy[J]. Acta Obstet Gynecol Scand, 2014, 93(7):661-668. DOI:10.1111/aogs.12383. [8] Galic V, Herzog TJ, Lewin SN, et al. Prognostic significance of adenocarcinoma histology in women with cervical cancer[J]. Gynecol Oncol, 2012, 125(2):287-291. DOI:10.1016/j.ygyno.2012.01.012. [9] Takeuchi S. Biology and treatment of cervical adenocarcinoma[J]. Chin J Cancer Res, 2016, 28(2):254-262. DOI:10.21147/j.issn.1000-9604.2016.02.11. [10] Sun L, Sheng X, Jiang J, et al. Surgical morbidity and oncologic results after concurrent chemoradiation therapy for advancedcervical cancer[J]. Int J Gynaecol Obstet, 2014, 25(2):111-115. DOI:10.1016/j.ijgo.2013.07.041. [11] 罗敏,杨佳欣,沈铿,等. 局部晚期宫颈腺癌根治性放疗后辅助子宫切除术的临床分析[J] 生殖医学杂志,2012,21(1):4-7. DOI:10.3969/j.issn.1004-3845.2012.01.002. Luo M, Yang JX, Shen K, t al. Clinical analysis of assisted hysterectomy after radical radiotherapy for locally advanced cervical adenocarcinoma[J] J Reproduct Med, 2012, 21(1):4-7. DOI:10.3969/j.issn.1004-3845.2012.01.002. [12] Vincens E, Balleyguier C, Rey A, et al. Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage Ⅰ b2/Ⅱ cervical carcinoma with chemoradiation therapy:correlation of radiologic findings with surgicopathologic results[J]. Cancer, 2008, 113(8):2158-2165. DOI:10.1002/cncr.23817. [13] Hequet D, Marchand E, Place V, et al. Evaluation and impact of residual disease in locally advanced cervical cancer after concurrent chemoradiation therapy:results of a multicenter study[J]. Eur J Surg Oncol, 2013, 39(12):1428-1434. DOI:10.1016/j.ejso.2013.10.006. [14] Motton S, Houvenaeghel G, Delannes M, et al. Results of surgery after concurrent chemoradiotherapy in advanced cervical cancer:comparison of extended hysterectomy and extrafascial hysterectomy[J]. Int J Gynecol Cancer, 2010, 20(2):268-275. DOI:10.1111/igc.0b013e3181c9e385. [15] Fanfani F, Vizza E, Landoni F, et al. Radical hysterectomy after chemoradiation in FIGO stage Ⅲ cervical cancer patients versus chemoradiation and brachytherapy:complications and 3-years survival[J]. Eur J Surg Oncol, 2016, 42(10):1519-1525. DOI:10.1016/j.ejso.2016.05.011. [16] Morice P, Rouanet P, Rey A, et al. Results of the GYNECO 02 study, an FNCLCC phase Ⅲ trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage Ⅰ b2 or Ⅱ cervical cancer[J]. Oncologist, 2012, 17(1):64-71. DOI:10.1634/theoncologist.2011-0276. [17] Yang J, Shen K. Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma[J]. J Gynecol Oncol, 2016, 27(4):e40. DOI:10.3802/jgo.2016.27.e40. [18] Pervin S, Ruma FI, Rahman K, et al. Adjuvant hysterectomy in patients with residual disease after radiation for locally advanced cervical cancer:a prospective longitudinal study[J]. J Glob Oncol, 2019, 5(1):1-7. DOI:10.1200/jgo.18.00157. [19] Houvenaeghel G, Lelievre L, Buttarelli M, et al. Contribution of surgery in patients with bulky residual disease after chemoradiation for advanced cervical carcinoma[J]. Eur J Surg Oncol, 2007, 33(4):498-503. DOI:10.1016/j.ejso.2006.10.011. [20] Tangjitgamol S, Tharavichitkul E, Tovanabutra C, et al. A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients:ACTLACC trial[J]. J Gynecol Oncol, 2019, 30(4):e82. DOI:10.3802/jgo.2019.30.e82. [21] Duenas-Gonzalez A, Zarba JJ, Patel F, et al. Phase Ⅲ, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage ⅡB to IVA carcinoma of the cervix[J]. J Clin Oncol, 2011, 29(13):1678-1685. DOI:10.1200/JCO.2009.25.9663. [22] Tang J, Tang Y, Yang J, et al. Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma[J]. Gynecol Oncol, 2012, 125(2):297-302. DOI:10.1016/j.ygyno.2012.01.033.
2020, Vol. 29 
